<SEC-DOCUMENT>0001193125-25-286212.txt : 20251118
<SEC-HEADER>0001193125-25-286212.hdr.sgml : 20251118
<ACCEPTANCE-DATETIME>20251118162443
ACCESSION NUMBER:		0001193125-25-286212
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20251117
FILED AS OF DATE:		20251118
DATE AS OF CHANGE:		20251118

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Bredt David
		CENTRAL INDEX KEY:			0002022087
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42121
		FILM NUMBER:		251495087

	MAIL ADDRESS:	
		STREET 1:		C/O RAPPORT THERAPEUTICS
		STREET 2:		1325 BOYLSTON ST., SUITE 401
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02215

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Rapport Therapeutics, Inc.
		CENTRAL INDEX KEY:			0002012593
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				880724208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		99 HIGH STREET
		STREET 2:		SUITE 2100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		857-321-8020

	MAIL ADDRESS:	
		STREET 1:		99 HIGH STREET
		STREET 2:		SUITE 2100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-11-17</periodOfReport>

    <issuer>
        <issuerCik>0002012593</issuerCik>
        <issuerName>Rapport Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>RAPP</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002022087</rptOwnerCik>
            <rptOwnerName>Bredt David</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>RAPPORT THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>99 HIGH STREET, SUITE 2100</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02110</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>Chief Scientific Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>true</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-11-17</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>3156</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>24.8399</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>406486</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-11-17</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>5344</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>25.3922</value>
                    <footnoteId id="F3"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>401142</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.</footnote>
        <footnote id="F2">The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.16 to $25.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.</footnote>
        <footnote id="F3">The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.16 to $25.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Troy Ignelzi, Attorney-in-Fact</signatureName>
        <signatureDate>2025-11-18</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
